Minimally invasive surgery, HD imaging upgrades drive Taiwan’s neuroendoscopy adoption

The market remains small but highly specialised.

Taiwan’s neuroendoscopes market is expected to grow steadily, driven by rising neurological disorders, an aging population, and increased adoption of minimally invasive neurosurgical technologies, according to GlobalData.

The market is projected to expand at a compound annual growth rate of around 4% through 2036. Taiwan accounted for nearly 3% of the Asia-Pacific neuroendoscopes market in 2025.

The firm noted that demand in Asia-Pacific is led by Japan and China, whilst Taiwan remains a smaller, highly specialised market centered in tertiary hospitals.

Growth is expected to come mainly from upgrades to high-definition imaging systems and minimally invasive surgical workflows, rather than broad-based adoption.

“In Taiwan, adoption is expected to remain specialised and procurement-led, with growth tied to gradual upgrades to high-definition endoscopic visualisation and minimally invasive neurosurgical workflows,” said Aakansha Pankaj, medical devices analyst at GlobalData. “However, the high capital and servicing costs of imported reusable systems can constrain wider penetration beyond leading institutions, potentially sustaining a center-of-excellence–driven adoption pattern.”

Recent developments include Brain Navi Biotechnology receiving approval from the Taiwan Food and Drug Administration for its single-use 3D neuroendoscope, “KrystoLens.”

The disposable system is designed to remove sterilisation and reprocessing steps, improving operating room efficiency and enabling a shift toward more predictable per-procedure costs.

Future market growth will depend on broader access to advanced imaging tools, hospital procurement decisions, and demonstrated clinical benefits in real surgical settings.